Taysha Gene Therapies Inc. TSHA on Wednesday announced details of its planned pivotal Part B trial design for TSHA-102 following written alignment from the U.S. Food and Drug Administration (FDA).Single-arm, open-label trial with patients serving as their control (intend N=15).Enrollment of females in the developmental plateau population of Rett syndrome (≥ 6 years).The primary endpoint will assess developmental milestone gain or regain.The safety of TSHA-102 will be evaluated in females in the pre-developm ...